StreetAlpha.app
Home › Stocks › PEPG

PepGen Inc. (PEPG)

Healthcare
$3.88
▼ −7.40%
LAST CLOSE · NOV 17

PepGen develops treatments for severe neuromuscular diseases, starting with myotonic dystrophy type 1. It last closed at $3.88 on Nov 17, down 7.40% on the day. The average 12-month price target from 3 analysts is $15.00 (+286.6% from the last close), with a high of $20.00 and a low of $10.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $278K, the largest $143K.

AI Auto Pilots
Is PEPG in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$73.3M
EPS (diluted)
−$0.77
Free cash flow
−$63.3M
Valuation
Market cap
$268.7M
69.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.0M
At Sep 30
Shareholder equity
$103.1M
Shares outstanding
69.3M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$27.3M−$27.3MFY2021FY2022: −$69.1M−$69.1MFY2022FY2023: −$78.6M−$78.6MFY2023FY2024: −$90.0M−$90.0MFY2024FY2025: −$89.7M−$89.7MFY2025

From PEPG's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on PEPG in the past 90 days
Average 12-month target
$15.00
▲ 286.6% upside

Based on 3 analysts who set a price target on PEPG in the past 90 days. The average target is $15.00, with a high of $20.00 and a low of $10.00, compared with the last close of $3.88.

Low $10.00Avg $15.00High $20.00
Blue marker: last close $3.88
Highest target$20.00
Average target$15.00
Lowest target$10.00
Latest rating changes
GuggenheimMaintained
Nov 13Buy$15
WedbushMaintained
Nov 11Buy$10
HC Wainwright & Co.Reiterated
Sep 9Buy$20
Craig-HallumInitiated
Jun 16Buy$11
DateFirmActionRatingPrice target
Nov 13GuggenheimMaintainedBuy$15
Nov 11WedbushMaintainedBuy$10
Sep 9HC Wainwright & Co.ReiteratedBuy$20
Jun 16Craig-HallumInitiatedBuy$11
Loading…

Technical Analysis

PEPG · as of the Nov 17 close · updated after every close
Turning up

The stock is 20% above its 20 day and 27% above its 50 day average. It is 25% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 59). The nearest support is the Pivot S1 at $3.60, and the nearest resistance the Pivot at $3.90.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityHigh, 13.9%/day
Key levels
$7.8052 week high+101.0%
$6.44Swing high (Nov 10)+66.0%
$4.18Pivot R1+7.7%
$3.90Pivot+0.5%
$3.88Last close
$3.60Pivot S1−7.2%
$3.1120 day average−19.8%
$2.92200 day average−24.7%
$2.91Swing low (Sep 1)−25.0%
$2.8350 day average−27.1%
$2.66100 day average−31.4%
$1.3152 week low−66.2%
Indicators
RSI (14)58.55Middle of its rangeNeutral
MACD0.47Above its signal lineBullish
Stochastic45.6Middle of its rangeNeutral
ADX (14)26.9Trending up
Williams %R-60.7Oversold below −80, overbought above −20Neutral
CCI (20)51.9Oversold below −100, overbought above 100Neutral
Rate of change+57.7%Change over 10 sessionsBullish
ATR (14)$0.54Typical daily range, 13.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PEPG

What happened before

See how PEPG did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PEPG usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PEPG has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PEPG in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$278K
Largest print
$143K
Loading…

PEPG Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲45 buying vs 30 selling
  • ▲Held by funds +3.2 pts
  • ▲Funds holding +12
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding8472+16.7%
In funds' top 1000–
Held by funds78.4%75.2%+3.2 pts
New / increased20 / 257 / 21+60.7%
Reduced / sold out22 / 825 / 27−42.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PEPG institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PEPG is in one of them and how their past PEPG trades turned out.

PEPG in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PEPG in an article yet. Here's the latest on the wider market.

About PepGen

PepGen is a biotechnology company based in Boston, Massachusetts, that develops treatments for severe neuromuscular and neurologic diseases. Its lead candidate, PGN-EDODM1, is being developed for myotonic dystrophy type 1, a multi-system muscle disease with no approved therapies. The company's proprietary delivery platform uses peptides designed to carry short strands of genetic material into muscle and other cells, aiming to reach the cell nucleus. Its treatments remain in clinical trials and are intended for patients with these conditions.

Headquarters
Boston, MA